Nebenwirkungen · Tookad
TOOKAD 183 mg powder for solution for injection TOOKAD 366 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 10
HOS-136024 · Präparat HOS-097808
Erectile dysfunction In the Phase III European study, 60 (30.5 %) of patients in the TOOKAD-VTP arm experienced erectile dysfunction and 16 (8.1 %) experienced ejaculation failure. 53 (26.9 %) patients experienced erectile dysfunction for more than 6 months, including 34 (17.3 %) patients in whom the erectile dysfunction had not resolved at the end of the study. When the analysis was restricted to patients that underwent unilateral VTP, 33 (16.8 %) patients experienced erectile dysfunction for more than 6 months, including 17 (8.6 %) patients in whom the erectile dysfunction had not resolved at the end of the study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-12-07T01:00:00Z · SHA-256 86ab6205066703c9c0efe5f9fcb6f836848dd067cf287be0e096ac7a8110e9b4 · Passage db55f4f4c0daf0df3832549f7f87b721ffa9f50e0bed9296f479aeade86e3035 · Zeichen 9237–9860 im Abschnitt